This 24-week , placebo-controlled , double-blind , randomized study ( NCT00791921 ) investigated efficacy and safety of certolizumab pegol ( CZP ) in Japanese rheumatoid arthritis ( RA ) patients in whom methotrexate ( MTX ) can not be administered .